Ibrutinib is a specific inhibitor of the Bruton kinase (BTK) and it has been recently approved for the therapy of relapsed/refractory mantle cell lymphomas (MCL), chronic lymphocytic leukemia (CLL) and Waldenstrom macroglobulinemia (WM) (20). Here, BTK is linked to mantle cell lymphoma.